Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risankizumab Pregnancy Exposure Registry: a Prospective Observational Study on the Safety of Risankizumab Exposure in Pregnant Women and Their Offspring

NCT04846959 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04846959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04846959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risankizumab Pregnancy Exposure Registry: a Prospective Observational Study on the Safety of Risankizumab Exposure in Pregnant Women and Their Offspring
Lead sponsor
AbbVie
Phase
Observational
Overall status
Recruiting
Start date
July 30, 2021
Completion date
June 30, 2032
Enrollment
818 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis, psoriatic arthritis, crohn's disease, or other conditions for which risankizumab is an fda-approved treatment